Last reviewed · How we verify
Treatment of acute, uncomplicated Plasmodium falciparum malaria — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| artesunate-amodiaquine (AS-AQ) | artesunate-amodiaquine (AS-AQ) | Yale University | Artemisinin derivative + aminoquinoline antimalarial combination | Plasmodium falciparum heme iron (Fe2+), parasite DNA, heme polymerase |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Yale University · 1 drug in Treatment of acute, uncomplicated Plasmodium falciparum malaria
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Treatment of acute, uncomplicated Plasmodium falciparum malaria:
- Treatment of acute, uncomplicated Plasmodium falciparum malaria treatment updates — RSS
- Treatment of acute, uncomplicated Plasmodium falciparum malaria treatment updates — Atom
- Treatment of acute, uncomplicated Plasmodium falciparum malaria treatment updates — JSON
Cite this brief
Drug Landscape (2026). Treatment of acute, uncomplicated Plasmodium falciparum malaria — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/treatment-of-acute-uncomplicated-plasmodium-falciparum-malaria. Accessed 2026-06-10.
Related
- Treatment of acute, uncomplicated Plasmodium falciparum malaria full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing